Tror folk på en opjustering fra AMBU ?
-
DSDK Forventes en opjustering?
https://www.ambu.com/corporate-info/investors/news-from-ambu
The sales outlook for the full year was upgraded on 6 April 2020 due to the higher-than-expected growth in Q2. The outlook for organic revenue growth was increased from "16-22%" to "26-30%", and the guidance on the number of endoscopes sold was increased from "approx. 900,000" to "more than 1 million".
The outlook for the EBIT margin before special items was suspended on 6 April 2020 and is now resumed at 12-14%. This interval reflects our decision to accelerate our commercial infrastructure expansion into GI and urology and ensure the successful launches of aScope
Duodeno and aScope 4 Cysto.
The outlook for the financial year 2019/20 is:
Organic growth in the range of 26-30%.
EBIT margin before special items in the range of 12-14%.
Sales of more than 1 million endoscope units.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind